These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. Nakum S; Cavanna AE Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525 [TBL] [Abstract][Full Text] [Related]
24. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report]. Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028 [No Abstract] [Full Text] [Related]
25. Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease. Girard R; Obeso I; Thobois S; Park SA; Vidal T; Favre E; Ulla M; Broussolle E; Krack P; Durif F; Dreher JC Brain; 2019 Jan; 142(1):146-162. PubMed ID: 30590514 [TBL] [Abstract][Full Text] [Related]
26. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist. Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612 [TBL] [Abstract][Full Text] [Related]
28. Clinical spectrum of impulse control disorders in Parkinson's disease. Weintraub D; David AS; Evans AH; Grant JE; Stacy M Mov Disord; 2015 Feb; 30(2):121-7. PubMed ID: 25370355 [TBL] [Abstract][Full Text] [Related]
29. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Claassen DO; van den Wildenberg WPM; Ridderinkhof KR; Jessup CK; Harrison MB; Wooten GF; Wylie SA Behav Neurosci; 2011 Aug; 125(4):492-500. PubMed ID: 21604834 [TBL] [Abstract][Full Text] [Related]
30. Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease. Choi JH; Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho JW Neurodegener Dis; 2019; 19(5-6):171-177. PubMed ID: 32454490 [TBL] [Abstract][Full Text] [Related]
31. [Impulsive-compulsive syndrome in Parkinson's disease]. Nikitina AV; Fedorova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929 [TBL] [Abstract][Full Text] [Related]
32. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease]. Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158 [TBL] [Abstract][Full Text] [Related]
33. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. Fusaroli M; Raschi E; Contin M; Sambati L; Menchetti M; Fioritti A; Poluzzi E Parkinsonism Relat Disord; 2021 Sep; 90():79-83. PubMed ID: 34399162 [TBL] [Abstract][Full Text] [Related]
34. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214 [TBL] [Abstract][Full Text] [Related]
35. Prevention of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Case Report. Luchsinger WT; Gambhir N; DeMoss D Prim Care Companion CNS Disord; 2018 Apr; 20(2):. PubMed ID: 29701928 [No Abstract] [Full Text] [Related]